Categories: News

DRUID AI Raises $31 Million Series C to Accelerate Agentic AI Platform Growth Under New CEO Joseph Kim

NEW YORK and LONDON and BUCHAREST, Romania, Sept. 17, 2025 /PRNewswire/ — DRUID AI today announced it has secured $31 million in Series C financing to advance the global expansion of its enterprise-ready agentic AI platform under the leadership of its new CEO Joseph Kim. The strategic investment was led by Cipio Partners, with participation from TQ Ventures, Karma Ventures, Smedvig, and Hoxton Ventures.

- Advertisement -

 

- Advertisement -

“Customer success is what it’s all about, and delivering real business outcomes requires understanding companies’ pain points and introducing innovations that help those customers address their complex challenges”, mentioned Kim. Previously, Kim was CEO of Sumo Logic. He serves on the boards of directors of SmartBear and Andela. He was also a senior operating partner at Francisco Partners, CPTO at Citrix, SolarWinds, and Hewlett Packard Enterprise, and chief architect at GE.

- Advertisement -

Roland Dennert, managing partner at the premier global growth equity fund Cipio Partners, explained: “Our investment will help accelerate DRUID AI’s expansion into the U.S. and elsewhere, fuel further technological advancements, and strengthen its position as a global leader in enterprise AI solutions.”

- Advertisement -

The appointment of Kim as CEO and the new funding come on the heels of DRUID AI earning a Challenger spot in the Gartner Magic Quadrant for Conversational AI Platforms for 2025. This is just the latest development validating the maturity of DRUID AI’s platform and its readiness to deliver business results in a market that is experiencing rapid advancement and adoption.

- Advertisement -

In 2024, DRUID AI grew ARR 2.7x year-over-year. Its award-winning platform has powered more than 1 billion conversations across thousands of agents. In addition, the DRUID AI global partner ecosystem has attracted industry giants Microsoft, Genpact, Cognizant, and Accenture.

- Advertisement -

DRUID AI is trusted by more than 300 global clients across banking, financial services, government, healthcare, higher education, manufacturing, retail, and telecommunications. Leading organizations such as AXA Insurance, Carrefour, the Food and Drug Administration (FDA), Georgia Southern University, Kmart Australia, Liberty Global Group, MatrixCare, National Health Service, and Orange Auchan have adopted DRUID AI to redefine the way they operate.

- Advertisement -

Powered by advanced agentic AI and driven by the DRUID Conductor, its core orchestration engine, the DRUID platform enables businesses to deploy AI agents and intelligent applications that streamline processes effortlessly, integrate seamlessly with existing systems, and efficiently fulfill complex requests. DRUID AI’s end-to-end platform delivers 98% first response accuracy.

- Advertisement -

To learn more, visit www.druidai.com.

- Advertisement -

Contact:
Raluca Rotaru
Raluca.rotaru@druidai.com

- Advertisement -

Photo: https://mma.prnewswire.com/media/2774339/DRUID_AI_CEO.jpg
Logo: https://mma.prnewswire.com/media/2774340/DRUID_AI_Logo.jpg

- Advertisement -

 

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/druid-ai-raises-31-million-series-c-to-accelerate-agentic-ai-platform-growth-under-new-ceo-joseph-kim-302559010.html

- Advertisement -

Recent Posts

Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026 16:01 ET  | Source: Ocular Therapeutix, Inc. BEDFORD, Mass., Feb. 06, 2026…

2 hours ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026 16:01 ET  | Source: NewAmsterdam Pharma N.V. NAARDEN, The Netherlands and MIAMI,…

2 hours ago

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing…

2 hours ago

The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies

AlUla, Saudi Arabia, Feb. 7, 2026 /PRNewswire/ -- The second edition of the AlUla Conference…

2 hours ago

Roches fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint…

2 hours ago

Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

February 06, 2026 17:17 ET  | Source: Lexicon Pharmaceuticals, Inc. THE WOODLANDS, Texas, Feb. 06,…

2 hours ago